Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.

Details

Serval ID
serval:BIB_184FA0493B6C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Journal
Journal of clinical oncology
Author(s)
Ambros I.M., Tonini G.P., Pötschger U., Gross N., Mosseri V., Beiske K., Berbegall A.P., Bénard J., Bown N., Caron H., Combaret V., Couturier J., Defferrari R., Delattre O., Jeison M., Kogner P., Lunec J., Marques B., Martinsson T., Mazzocco K., Noguera R., Schleiermacher G., Valent A., Van Roy N., Villamon E., Janousek D., Pribill I., Glogova E., Attiyeh E.F., Hogarty M.D., Monclair T.F., Holmes K., Valteau-Couanet D., Castel V., Tweddle D.A., Park J.R., Cohn S., Ladenstein R., Beck-Popovic M., De Bernardi B., Michon J., Pearson ADJ, Ambros P.F.
ISSN
1527-7755 (Electronic)
ISSN-L
0732-183X
Publication state
Published
Issued date
01/11/2020
Peer-reviewed
Oui
Volume
38
Number
31
Pages
3685-3697
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.
Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.
Patients with stage 1 tumors had an excellent outcome (5-year event-free survival [EFS] ± standard deviation [SD], 95% ± 2%; 5-year overall survival [OS], 99% ± 1%). In contrast, patients with stage 2 tumors had a reduced EFS in both age groups (5-year EFS ± SD, 84% ± 3% in patients < 18 months of age and 75% ± 7% in patients ≥ 18 months of age). However, OS was significantly decreased only in the latter group (5-year OS ± SD in < 18months and ≥ 18months, 96% ± 2% and 81% ± 7%, respectively; P = .001). In < 18months, relapses occurred independent of segmental chromosome aberrations (SCAs); only 1p loss decreased EFS (5-year EFS ± SD in patients 1p loss and no 1p loss, 62% ± 13% and 87% ± 3%, respectively; P = .019) but not OS (5-year OS ± SD, 92% ± 8% and 97% ± 2%, respectively). In patients ≥ 18 months, only SCAs led to relapse and death, with 11q loss as the strongest marker (11q loss and no 11q loss: 5-year EFS ± SD, 48% ± 16% and 85% ± 7%, P = .033; 5-year OS ± SD, 46% ± 22% and 92% ± 6%, P = .038).
Genomic aberrations of resectable non-MYCN-amplified stage 2 neuroblastomas have a distinct age-dependent prognostic impact. Chromosome 1p loss is a risk factor for relapse but not for diminished OS in patients < 18 months, SCAs (especially 11q loss) are risk factors for reduced EFS and OS in those > 18months. In older patients with SCA, a randomized trial of postoperative chemotherapy compared with observation alone may be indicated.
Keywords
Age Factors, Chromosome Aberrations, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 11, Clinical Trials as Topic, Diploidy, Gene Amplification, Genomics, Humans, Infant, N-Myc Proto-Oncogene Protein/genetics, Neoplasm Staging, Neuroblastoma/genetics, Neuroblastoma/pathology, Neuroblastoma/surgery, Prognosis, Progression-Free Survival, Survival Rate
Pubmed
Web of science
Open Access
Yes
Create date
14/09/2020 8:36
Last modification date
16/04/2024 7:11
Usage data